Last reviewed 2026-05-28 · How we verify

CX717 200 mg

RespireRx · Phase 2 active Small molecule ✓ Verified May 2026 Quality 0/100

CX717 200 mg is a Small molecule drug developed by RespireRx. It is currently in Phase 2 development. Also known as: Low Dose.

CX717 is a small molecule ampakine compound. It was studied in a clinical trial for the treatment of adult Attention Deficit Hyperactivity Disorder (ADHD) at doses of 200 mg and 800 mg.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CX717 200 mg
Also known as	Low Dose
Sponsor	RespireRx
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

CX717 in the Treatment of Adult ADHD (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CX717 200 mg CI brief — competitive landscape report
CX717 200 mg updates RSS · CI watch RSS
RespireRx portfolio CI

Frequently asked questions about CX717 200 mg

What is CX717 200 mg?

CX717 200 mg is a Small molecule drug developed by RespireRx.

Who makes CX717 200 mg?

CX717 200 mg is developed by RespireRx (see full RespireRx pipeline at /company/respirerx).

Is CX717 200 mg also known as anything else?

CX717 200 mg is also known as Low Dose.

What development phase is CX717 200 mg in?

CX717 200 mg is in Phase 2.

Manufacturer: RespireRx — full pipeline
Also known as: Low Dose

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing